Content area
Full Text
Certolizumab pegol is a cost-effective alternative treatment for patients with moderate-to-severe rheumatoid arthritis (RA), with or without a risk-sharing scheme (RSS), in Finland, report researchers from that country.
The researchers developed a model to assess the cost effectiveness and budget impact of certolizumab pegol over a 5-year time period, with or without an rSs, at treatment initiation as an alternative option for patients...